Search research articles
Contact Us
Filters
Showing results (31-40 of 44) with videos related to
Page
of 5
Sort By:
EJNMMI Research
|
April 26, 2017
Therapeutic efficacy of α-radioimmunotherapy with different activity levels of the <sup>213</sup>Bi-labeled monoclonal antibody MX35 in an ovarian cancer model
Anna Gustafsson-Lutz, Tom Bäck, Emma Aneheim, et al.
Nuclear Medicine and Biology
|
November 28, 2006
Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity
Jörgen Elgqvist, Håkan Andersson, Tom Bäck, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 16, 2009
Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study
Håkan Andersson, Elin Cederkrantz, Tom Bäck, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 14, 2015
Absorbed Doses and Risk Estimates of (211)At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients
Elin Cederkrantz, Håkan Andersson, Peter Bernhardt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 9, 2004
Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression
Ase M Ballangrud, Wei-Hong Yang, Stig Palm, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 27, 2019
Intraperitoneal α-Emitting Radioimmunotherapy with <sup>211</sup>At in Relapsed Ovarian Cancer: Long-Term Follow-up with Individual Absorbed Dose Estimations
Andreas Hallqvist, Karin Bergmark, Tom Bäck, et al.
Nutrients
|
May 14, 2020
Antitumor, Anti-Inflammatory and Antiallergic Effects of <i>Agaricus blazei</i> Mushroom Extract and the Related Medicinal Basidiomycetes Mushrooms, <i>Hericium erinaceus</i> and <i>Grifola</i> <i>frondosa</i>: A Review of Preclinical and Clinical Studies
Geir Hetland, Jon-Magnus Tangen, Faiza Mahmood, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 3, 2006
Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose
Jörgen Elgqvist, Håkan Andersson, Tom Bäck, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 5, 2003
Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI
Stig Palm, Richard M Enmon, Cornelia Matei, et al.
Molecular Pharmaceutics
|
July 4, 2019
Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior
Yana Dekempeneer, Tom Bäck, Emma Aneheim, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 44) with videos related to
Sort By:
Page
of 5
EJNMMI Research
|
April 26, 2017
Therapeutic efficacy of α-radioimmunotherapy with different activity levels of the <sup>213</sup>Bi-labeled monoclonal antibody MX35 in an ovarian cancer model
Anna Gustafsson-Lutz, Tom Bäck, Emma Aneheim, et al.
Nuclear Medicine and Biology
|
November 28, 2006
Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity
Jörgen Elgqvist, Håkan Andersson, Tom Bäck, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 16, 2009
Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study
Håkan Andersson, Elin Cederkrantz, Tom Bäck, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 14, 2015
Absorbed Doses and Risk Estimates of (211)At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients
Elin Cederkrantz, Håkan Andersson, Peter Bernhardt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 9, 2004
Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression
Ase M Ballangrud, Wei-Hong Yang, Stig Palm, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 27, 2019
Intraperitoneal α-Emitting Radioimmunotherapy with <sup>211</sup>At in Relapsed Ovarian Cancer: Long-Term Follow-up with Individual Absorbed Dose Estimations
Andreas Hallqvist, Karin Bergmark, Tom Bäck, et al.
Nutrients
|
May 14, 2020
Antitumor, Anti-Inflammatory and Antiallergic Effects of <i>Agaricus blazei</i> Mushroom Extract and the Related Medicinal Basidiomycetes Mushrooms, <i>Hericium erinaceus</i> and <i>Grifola</i> <i>frondosa</i>: A Review of Preclinical and Clinical Studies
Geir Hetland, Jon-Magnus Tangen, Faiza Mahmood, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 3, 2006
Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose
Jörgen Elgqvist, Håkan Andersson, Tom Bäck, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 5, 2003
Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI
Stig Palm, Richard M Enmon, Cornelia Matei, et al.
Molecular Pharmaceutics
|
July 4, 2019
Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior
Yana Dekempeneer, Tom Bäck, Emma Aneheim, et al.
Page
of 5